... the past by the Food and Drug
Administration (FDA) for marketing based on trials using the FAB criteria.
Acute Myeloid Leukemia
Incidence
The incidence of acute myeloid leukemia (AML) is ~3.7 ... years after exposure,
and affected individuals have aberrations in chromosomes 5 and 7. Topoisomerase
II inhibitor–associated leukemias occur 1–3 years after exposure, and a...
... Continuous
activation of Flt3 and downstream target kinases, including signal transducer and
Chapter 104. Acute and Chronic
Myeloid Leukemia
(Part 3)
Immunophenotype and Relevance to the WHO ... commonly associated with younger age are t(8; 21) and t(l5;17); with older
age, del(5q) and del(7q). Myeloid sarcomas (see below) are associated with t(8; 21)
and...
... morphologically by abnormal
lobulation and deficient granulation.
Figure 104- 1
Chapter 104. Acute and Chronic
Myeloid Leukemia
(Part 4)
Clinical Presentation
Symptoms
Patients with AML most ... they are,
myeloid lineage is virtually certain (Fig 104- 1). Poor neutrophil function may be
noted by impaired phagocytosis and migration and morphologically by a...
... Chapter 104. Acute and Chronic
Myeloid Leukemia
(Part 5)
Morphology of AML cells. A. Uniform population of primitive
myeloblasts with immature chromatin, nucleoli in some cells, and ...
Ecchymosis and oozing from I
V sites (DIC, possible acute promyelocytic
leukemia)
Fever and tachycardia (signs of infection)
Papilledema, retinal infiltrates, cranial nerve abn...
... achievement of CR. In addition, patients who achieve
Chapter 104. Acute and Chronic
Myeloid Leukemia
(Part 6)
Most patients are anemic and thrombocytopenic at presentation.
Replacement of ... entering CR, the length of CR, and
the curability of AML. CR is defined after examination of both blood and bone
marrow. The blood neutrophil count must be ≥1000/µL and the...
... Chapter 104. Acute and Chronic
Myeloid Leukemia
(Part 7)
Acute Myeloid Leukemia: Treatment
Treatment of the newly diagnosed patient ... allogeneic stem cell
Figure 104- 2
Flow chart for the therapy of newly diagnosed acute myeloid leukemia.
For all forms of AML except acute promyelocytic leukemia (APL), standard
therapy includes ...
synthesis and...
... Chapter 104. Acute and Chronic
Myeloid Leukemia
(Part 8)
The hematologic toxicity of high-dose cytarabine-based induction ... been greater than that associated with 7 and 3 regimens. Toxicity
with high-dose cytarabine includes myelosuppression, pulmonary toxicity, and
significant and occasionally irreversible cerebellar ... each dose, and further high-dose
cytar...
...
Radiolabeled antibodies
Yttrium-90-labeled human M195
Chapter 104. Acute and Chronic
Myeloid Leukemia
(Part 9)
Treatment of Promyelocytic Leukemia
Tretinoin is an oral drug that induces the ... demonstrated. High-dose cytarabine significantly
prolonged CR and increased the fraction cured in patients with favorable [t(8; 21)
and inv(16)] and normal cytogen...
... Chapter 104. Acute and Chronic
Myeloid Leukemia
(Part 11)
Chronic Myelogenous Leukemia
Incidence
The incidence of chronic myelogenous leukemia (CML) is 1.5 per ... transition from a chronic
phase to an accelerated phase and on to blast crisis in a median time of 4 years.
Etiology
No clear correlation with exposure to cytotoxic drugs has been found, and...